Professional
Added to YB: 2025-06-05
Pitch date: 2025-03-31
LLY [neutral]
Eli Lilly and Company
+25.92%
current return
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Market Cap
$911.7B
Pitch Price
$812.58
Price Target
N/A
Dividend
0.68%
EV/EBITDA
29.72
P/E
44.47
EV/Sales
14.55
Sector
Pharmaceuticals
Category
growth
RiverPark Large Growth Fund Portfolio Holding: Eli Lilly and Company
LLY (holding update): Strong Q1 on weight-loss drugs Zepbound & Mounjaro despite capacity constraints. Expanding manufacturing to meet robust demand. Pipeline includes promising Alzheimer's, oncology & immunology therapies. Well-positioned for long-term revenue/earnings growth with market-leading products & growing FCF generation.
Read full article (1 min)